J.Safra Asset Management Corp Has $826,000 Position in Boston Scientific Corporation $BSX

J.Safra Asset Management Corp raised its position in Boston Scientific Corporation (NYSE:BSX) by 2.6% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 7,749 shares of the medical equipment provider’s stock after buying an additional 197 shares during the period. J.Safra Asset Management Corp’s holdings in Boston Scientific were worth $826,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Sound Income Strategies LLC boosted its position in Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the last quarter. 1248 Management LLC bought a new position in shares of Boston Scientific in the 1st quarter worth $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific in the 1st quarter worth $27,000. Oliver Lagore Vanvalin Investment Group bought a new position in shares of Boston Scientific in the 2nd quarter worth $37,000. Finally, Activest Wealth Management boosted its position in shares of Boston Scientific by 6,216.7% in the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 373 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares of the company’s stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at approximately $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

NYSE:BSX opened at $94.92 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock’s 50-day simple moving average is $101.75 and its 200 day simple moving average is $101.84. The company has a market cap of $140.64 billion, a P/E ratio of 56.50, a P/E/G ratio of 2.30 and a beta of 0.61. Boston Scientific Corporation has a 52-week low of $80.64 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific’s quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on BSX shares. Royal Bank Of Canada restated an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a research report on Monday, September 29th. Weiss Ratings restated a “buy (b-)” rating on shares of Boston Scientific in a research report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Wednesday, October 1st. Jefferies Financial Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Finally, Leerink Partners raised their price objective on Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Boston Scientific currently has an average rating of “Buy” and a consensus price target of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.